CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 199 filers reported holding CLOVIS ONCOLOGY INC in Q3 2015. The put-call ratio across all filers is 0.94 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $1,154,000 | -61.9% | 14,008 | -56.7% | 1.34% | -62.8% |
| Q2 2017 | $3,032,000 | +1386.3% | 32,385 | +912.0% | 3.60% | +1166.2% |
| Q1 2017 | $204,000 | -71.0% | 3,200 | -79.8% | 0.28% | -78.3% |
| Q4 2016 | $703,000 | -53.5% | 15,832 | -3.8% | 1.31% | -61.2% |
| Q3 2015 | $1,513,000 | – | 16,458 | – | 3.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |